389 related articles for article (PubMed ID: 15465203)
1. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
Souhami L; Seiferheld W; Brachman D; Podgorsak EB; Werner-Wasik M; Lustig R; Schultz CJ; Sause W; Okunieff P; Buckner J; Zamorano L; Mehta MP; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):853-60. PubMed ID: 15465203
[TBL] [Abstract][Full Text] [Related]
2. Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol: in regard to Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860).
Vordermark D; Kölbl O
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):296-7; author reply 297. PubMed ID: 15850943
[No Abstract] [Full Text] [Related]
3. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
4. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
Langer CJ; Ruffer J; Rhodes H; Paulus R; Murray K; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):113-9. PubMed ID: 11516860
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
6. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Deutsch M; Green SB; Strike TA; Burger PC; Robertson JT; Selker RG; Shapiro WR; Mealey J; Ransohoff J; Paoletti P
Int J Radiat Oncol Biol Phys; 1989 Jun; 16(6):1389-96. PubMed ID: 2542193
[TBL] [Abstract][Full Text] [Related]
7. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Tsao MN; Mehta MP; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):47-55. PubMed ID: 16111571
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
9. In regard to Dr. Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860).
Kondziolka D; Lunsford LD; Flickinger JC
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):614-5; author reply 615-6. PubMed ID: 15890607
[No Abstract] [Full Text] [Related]
10. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
11. High-dose BCNU with ABMT followed by radiation therapy in the treatment of supratentorial glioblastoma multiforme.
Linassier C; Benboubker L; Velut S; Calais G; Saudeau D; Jan M; Autret A; Berger C; Biron P; Colombat P
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S69-72. PubMed ID: 8899180
[No Abstract] [Full Text] [Related]
12. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Tsien C; Moughan J; Michalski JM; Gilbert MR; Purdy J; Simpson J; Kresel JJ; Curran WJ; Diaz A; Mehta MP;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):699-708. PubMed ID: 18723297
[TBL] [Abstract][Full Text] [Related]
13. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme.
Nwokedi EC; DiBiase SJ; Jabbour S; Herman J; Amin P; Chin LS
Neurosurgery; 2002 Jan; 50(1):41-6; discussion 46-7. PubMed ID: 11844233
[TBL] [Abstract][Full Text] [Related]
14. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
15. Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?
Lustig RA; Scott CB; Curran WJ
Am J Clin Oncol; 2004 Oct; 27(5):516-21. PubMed ID: 15596923
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023.
Cardinale R; Won M; Choucair A; Gillin M; Chakravarti A; Schultz C; Souhami L; Chen A; Pham H; Mehta M
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1422-8. PubMed ID: 16750317
[TBL] [Abstract][Full Text] [Related]
17. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
Grossman SA; O'Neill A; Grunnet M; Mehta M; Pearlman JL; Wagner H; Gilbert M; Newton HB; Hellman R;
J Clin Oncol; 2003 Apr; 21(8):1485-91. PubMed ID: 12697871
[TBL] [Abstract][Full Text] [Related]
18. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
19. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
Halperin EC; Herndon J; Schold SC; Brown M; Vick N; Cairncross JG; Macdonald DR; Gaspar L; Fischer B; Dropcho E; Rosenfeld S; Morowitz R; Piepmeier J; Hait W; Byrne T; Salter M; Imperato J; Khandekar J; Paleologos N; Burger P; Bentel GC; Friedman A
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):793-802. PubMed ID: 8598355
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme.
Cho KH; Hall WA; Lo SS; Dusenbery KE
Technol Cancer Res Treat; 2004 Feb; 3(1):41-9. PubMed ID: 14750892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
